Meeting Banner
Abstract #0585

Magnetic resonance imaging for confirmation of catheter-selective tumor-targeting liposomes distribution

Venkateswara R Gogineni1, El-Sayed H Ibrahim1, Dilip R Maddirela1, Dong-Hyun Kim2, and Sarah B White1

1Medical College of Wisconsin, Milwaukee, WI, United States, 2Northwestern University, Chicago, IL, United States

Hepatocellular carcinoma is the most common form of primary liver cancer, and globally it is the sixth most common cancer. In this study, we use liposomes that can co-encapsulate the therapeutic agent (oxaliplatin or gemcitabine) in addition to iron oxide nanoparticles to enable MRI-monitored local delivery of the therapeutic agent to limit proangiogenic responses in non-resectable liver tumors following transcatheter embolotherapies. The results showed increased R2* values in the tumor regions at one week post-infusion, compared to the surrounding liver parenchyma and to same regions immediately after infusion, which allows for confirmation of procedural success and proper catheter-selective tumor targeting.

This abstract and the presentation materials are available to members only; a login is required.

Join Here